Free Trial
→ SpaceX will mint billionaires. You won't be one of them. (From Behind the Markets) (Ad)tc pixel
NASDAQ:BJDX

Bluejay Diagnostics 11/7/2024 Earnings Report

Bluejay Diagnostics logo
$4.44 -0.10 (-2.20%)
Closing price 04:00 PM Eastern
Extended Trading
$4.47 +0.03 (+0.79%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Bluejay Diagnostics EPS Results

Actual EPS
-$32.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bluejay Diagnostics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bluejay Diagnostics Announcement Details

Quarter
Date
11/7/2024
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Bluejay Diagnostics' next earnings date is estimated for Wednesday, August 19, 2026, based on past reporting schedules.

Conference Call Resources

Bluejay Diagnostics Earnings Headlines

Bluejay Diagnostics, Inc. Closes $8.5 Million Private Placement to Extend Cash Runway for FDA Approval and Commercialization
June 5, 2026  |  quiverquant.comQ
Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
June 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/06/3307671/0/en/bluejay-diagnostics-announces-closing-of-up-to-23-7-million-private-placement-priced-at-the-market-under-nasdaq-rules.html
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analyst Lance Ippolito says the real opportunity is elsewhere. He's identified 5 dirt-cheap stocks at the forefront of this mega-IPO, including a space ticker that Goldman Sachs, BlackRock, and Morgan Stanley are all buying, a rare resource miner Elon's entire empire depends on, and the chip supplier Starlink satellites can't function without. Access his free SpaceX Investing Blackbook before IPO day arrives.tc pixel
June 17 at 1:00 AM  |  InvestPub (Ad)
Bluejay Nears Completion of Pivotal SYMON-II Sepsis Trial
June 5, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/BJDX/pressreleases/1199073/bluejay-nears-completion-of-pivotal-symon-ii-sepsis-trial/
Bluejay Diagnostics Forms U.S. Manufacturing Partnership for Symphony
June 4, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/BJDX/pressreleases/2278235/bluejay-diagnostics-forms-us-manufacturing-partnership-for-symphony/
Why is Bluejay Diagnostics stock soaring Tuesday?
June 3, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/why-is-bluejay-diagnostics-stock-soaring-tuesday/ar-AA24EhQF
See More Bluejay Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bluejay Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bluejay Diagnostics and other key companies, straight to your email.

About Bluejay Diagnostics

Bluejay Diagnostics (NASDAQ:BJDX) (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting. The company has been pursuing clinical validation studies and regulatory clearances to support its plans for commercialization, working to demonstrate accuracy, reliability, and ease of use in both clinical and at-home environments.

Headquartered in Norcross, Georgia, Bluejay Diagnostics serves the U.S. market with strategic plans to expand internationally once regulatory approvals and distribution partnerships are in place. The management team brings together expertise in diagnostics, biotech development, and regulatory affairs, positioning the company to navigate the complex pathways associated with medical device registration and market entry. As Bluejay advances its development pipeline, it aims to improve patient access to timely, accurate, and patient-friendly diagnostic solutions for celiac disease and related disorders.

View Bluejay Diagnostics Profile
Earnings Tools